A related question.
Having found no dose-limiting toxicity with Cu67 attached to one targeting agent, can Clarity skip the dose escalatoon stage in therapeutic trials with Cu67 attached to different targeting agents?
Research/Valuation, page-205
-
- There are more pages in this discussion • 332 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$5.42 |
Change
0.350(6.90%) |
Mkt cap ! $1.689B | |||
| Open | High | Low | Value | Volume |
| $5.10 | $5.53 | $5.10 | $8.270M | 1.560M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1951 | $5.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.44 | 4280 | 2 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |